



Mutation analysis and characterisation of *F9* gene in haemophilia- B population of India

Sujayendra Kulkarni^{1,2}, Rajat Hegde⁴, Smita Hegde⁴, Suyamindra S. Kulkarni⁴, Suresh Hanagvadi⁵, Kusal K. Das⁶, Sanjeev Kolagi³, Pramod B. Gai⁴, Rudragouda Bulagouda¹

¹Human Genetics Laboratory, Department of Anatomy, Shri B.M Patil Medical College, Hospital and Research Centre, BLDE (Deemed to be University), Vijayapura, ²Division of Human Genetics (Central Research Lab), ³Department of Anatomy, S. Nijaliangappa Medical College, HSK Hospital and Research Center, Bagalkot, ⁴Karnataka Institute for DNA Research (KIDNAR), Dharwad, ⁵Department of Pathology, J. J. M. Medical College, Davangere, Karnataka, ⁶Laboratory of Vascular Physiology and Medicine, Department of Physiology, Shri B. M. Patil Medical College, Hospital and Research Centre, BLDE (Deemed to be University), Vijayapura, India

p-ISSN 2287-979X / e-ISSN 2288-0011
<https://doi.org/10.5045/br.2021.2021016>
Blood Res 2021;56:252-258.

Received on January 22, 2021
Revised on August 18, 2021
Accepted on August 25, 2021

Background

Hemophilia B (HB) is an X-linked bleeding disorder resulting from coagulation factor IX defects. Over 3,000 pathogenic, HB-associated mutations in the *F9* gene have been identified. We aimed to investigate the role of *F9* variants in 150 HB patients using sequencing technology.

Methods

F9 gene sequences were amplified from peripheral blood-derived DNA and sequenced on an Applied Biosystems (ABI) 3500 Sanger sequencing platform. Functional and structural predictions of mutant FIX were analyzed.

Results

Among 150 HB patients, 102 (68%), 30 (20%), and 18 (12%) suffered from severe, moderate, and mild HB, respectively. Genetic analysis identified 16 mutations, including 3 novel mutations. Nine mutations (7 missense and 2 stop-gain) were found to be pathogenic. Only 3 mutations (c.127C>T, c.470G>A, and c.1070G>A) were associated with different severities. While 2 mutations were associated with mild HB cases (c.304C>T and c.580A>G), 2 (c.195G>A and c.1385A>G) and 3 mutations (c.223C>T, c.1187G>A, and c.1232G>A) resulted in moderate and severe disease, respectively. Additionally, 1 mutation each was associated with mild-moderate (c.*1110A>G) and mild-severe HB disease (c.197A>T), 4 mutations were associated with moderate-severe HB cases (c.314A>G, c.198A>T, c.676C>T, and c.1094C>A). FIX concentrations were lower in the mutated group (5.5±2.5% vs. 8.0±2.5%). Novel p.E66D and p.S365 mutations were predicted to be pathogenic based on changes in FIX structure and function.

Conclusion

Novel single nucleotide polymorphisms (SNPs) largely contributed to the pathogenesis of HB. Our study strongly suggests that population-based genetic screening will be particularly helpful to identify risk prediction and carrier detection tools for Indian HB patients.

Key Words Hemophilia B, *F9* gene, Stop-gain mutation, Missense mutation, India

Correspondence to

Rudragouda Bulagouda, M.D.
Human Genetics Laboratory, Department
of Anatomy, Shri B.M Patil Medical
College, Hospital and Research Centre,
BLDE (Deemed to be University),
Vijayapura 586101, India
E-mail: drravisb2012@gmail.com

© 2021 Korean Society of Hematology

INTRODUCTION

Hemophilia is an X-linked blood disorder that causes sustained bleeding after injuries or trauma. Symptoms mainly include bleeding in the joints and muscles. The term hemo-

philia was first used by Friedrich Hopff, University of Zurich, in 1828 [1, 2]. Hemophilia B (HB) is caused by defects in coagulation factor IX. It is also called “Christmas disorder”, after it was identified by Stephen Christmas in 1952 [3]. FIX activity can be classified as severely (<1%), moderately (1-5%), and mildly (5-30%) impaired [1, 4, 5]. HB is less common

than hemophilia A (HA) (1 in 25,000 males vs. 1 in 5,000 males worldwide) [6, 7]. Approximately 14,000 people with hemophilia have been registered at the Haemophilia Federation of India; however, hemophilia remains under-diagnosed and many cases are thus not registered. HA occurs in 1 out of 10,000 male births, while HB occurs in 1 out of 30,000 male births [8].

The *F9* gene (Xq27.1-q2.2) is approximately 33.5 kb in length and contains eight exons [6, 9]. FIX is homologous to clotting factors VII (FVII) and XI (FXI). It plays a crucial role in blood coagulation and is synthesized in the liver as a vitamin K-dependent serine protease (SP) precursor [1]. FIX circulates in plasma as a glycoprotein. During blood coagulation, inactive FIX is converted into an active SP called Factor IXa. This activation process occurs in two ways: through intrinsic and extrinsic pathways. In the course of the intrinsic pathway, Factor IXa activates FIX in the presence of calcium ions. During the extrinsic pathway, FIX is activated by factor VIIa in the presence of calcium and lipoprotein [10]. FIX protein is composed of a γ -carboxyglutamic acid-rich (Gla) domain, two epidermal growth factor-like domains (EGF1 and EGF2), and an SP domain [6].

Recently, more than 3,000 pathogenic mutations and neutral polymorphisms have been identified in the *F9* gene, and these mutations have been documented in various online hemophilia databases [6, 11, 12]. In this study, we analyzed the *F9* genes of 150 HB patients from the hemophilia societies of Karnataka, India, for molecular changes using sequencing technology.

MATERIALS AND METHODS

Sample collection

This study was approved by the Institutional Ethical Committee of Shri B. M. Patil Medical College, Hospital and Research Centre, BLDE (Deemed to be University), Vijayapura (Ref. No.: BLDE (DU)/IEC/340/2018-19), and the SNMC Institutional Ethics Committee of Human Subject Research, Bagalkot (Ref. No.: SNMC/IECHSR/2018-19/A-B2/1.1). Written informed consent was obtained from all HB patients before blood sample collection. A total of 150 HB patients were included in this study, which were followed up at 12 different hemophilia societies across the Karnataka state of India. A detailed clinical history was obtained from all HB patients.

F9 gene analysis

Peripheral blood from HB patients was collected in EDTA vacutainers (BD, Franklin Lakes, NJ, USA). Prior to DNA isolation, the FIX concentration was measured and inhibitor assay were performed. DNA was extracted from peripheral blood using a blood and tissue DNA extraction kit (QIAGEN, Hilden, Germany). All exonic regions were amplified and the products were sequenced on an Applied Biosystems (ABI) 3500 Sanger sequencing platform using the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, Waltham, MA, USA). Results were analyzed using DNA sequence analysis software v5.4.

Bioinformatics analysis

The pathogenicity of the novel non-synonymous variants was analyzed using bioinformatics tools, such as PROVEAN

Table 1. Clinicopathological characteristics of the study population.

Clinicopathological parameters	Disease severity		
	Severe (Factor IX < 1%), N=102 (68%)	Moderate (Factor IX 1–5%), N=30 (20%)	Mild (Factor IX > 5%), N=18 (12%)
Mean factor IX levels (%)	0.6±0.2	2.5±1.3	8.0±2.6
Family history of bleeding (N)	80	10	7
Mean age of onset (yr)	2.0±1.0	7.5±2.8	10.0±3.5
Mutation frequency (within group)	48% (49/102)	86.7% (26/30)	83.3% (15/18)
Inhibitor-positive (N)	23	11	4
Inhibitor-negative (N)	79	19	14
Hemoglobin concentration	Normal	Normal	Normal
Platelet count	Normal	Normal	Normal
Prothrombin time	Normal	Normal	Normal
Activated partial thromboplastin time	High	High	High
Bleeding sites			
Joints	55 (54%)	19 (63.3%)	12 (66.7%)
Gum	17 (16.7%)	6 (20%)	4 (22.2%)
Muscle	13 (12.7%)	1 (3.3%)	2 (11.1%)
Epistaxis	7 (6.9%)	4 (13.3%)	0
Petechiae	10 (9.8%)	0	0

(http://provean.jcvi.org/seq_submit.php), PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/index.shtml>), PHD SNP (<https://snps.biofold.org/phd-snp/phd-snp.html>), SNPs & GO (<https://snps.biofold.org/snps-and-go/snps-and-go.html>), PANTHER (<http://www.pantherdb.org/>), and SNAP2 (<https://www.rostlab.org/services/snap/>). The conservation property of missense variants was investigated using the Clustal Omega multiple sequence alignment tool (<https://www.ebi.ac.uk/Tools/msa/clustalo/>). A 3D model of wild type and mutant FIX proteins was predicted using the Swiss model (<https://swissmodel.expasy.org/>), and the results were visualized and analyzed using the UCSF Chimera program.

RESULTS

Of the 150 HB patients included in this study, 102 (68%; FIX concentration, 0.6±0.2; age of onset, 2.0±1.0 y), 30 (20%; FIX concentration, 2.5±1.3; age of onset, 7.5±2.8 y), and

18 (12%; FIX concentration, 8.0±2.6; age of onset, 10.0±3.5y) suffered from severe, moderate, and mild HB, respectively. The detailed clinicopathological parameters are summarized in **Table 1**. In our study, we recorded 16 mutations. Of those, 1 was a synonymous mutation, 12 were missense mutations, 2 were stop-gain mutations, and 1 was a 3' UTR variant. Notably, 13 (81.25%) mutations were previously reported, but 3 (18.75%) were novel mutations, which had not been entered into any of the human SNP databases. The majority of the mutations were found in exon 8 of the gene and largely comprised missense mutations. Exon 8 showed a high number of mutations compared to other exons of the *F9* gene (**Fig. 1**, **Table 2**).

The novel missense mutation c.198A>T was found in the *F9* genes of 4 patients with moderate HB, with a mean FIX concentration of 2.0±0.5 and a mean age of onset of 7±1.0, as well as in 7 patients with severe HB, with a mean FIX concentration of 0.3±0.5 and a mean age of onset of 1.5±0.5. This mutation was observed at a high rate among




Fig. 1. Graphical representation of the distribution of the mutations within the *Factor 9 (F9)* gene.

Table 2. List of mutations recorded in the *F9* genes of our study cohort.

Mutation type	Nucleotide change	cDNA position	Amino acid change	Exon	Status	Frequency, N (%)
Missense	g.11313C>T	c.127C>T	p.R43W	2	Reported (rs1603264205)	9 (6.0%)
Missense	g.11381G>A	c.195G>A	p.M65I	2	Reported (rs763568424)	1 (0.66%)
Missense	g.11383A>T	c.197A>T	p.E66V	2	Reported (CM940423)	3 (2.0%)
Missense	g.11384A>T	c.198A>T	p.E66D	2	Not reported	12 (8.0%)
Stop-gain	g.11409 C>T	c.223C>T	p.R75 ^{a)}	2	Reported (rs137852227)	2 (1.33%)
Missense	g.15369 T>C	c.304C>T	p.C102R	4	Reported (CM960574)	2 (1.33%)
Missense	g.22664 T>C	c.314A>G	p.G143R	5	Reported (CM940499)	4 (2.66%)
Missense	g.22706 G>A	c.470G>A	p.C157Y	5	Reported (rs1367198680)	17 (11.33%)
Missense	g.25386 A>G	c.580A>G	p.T194A	6	Reported (rs6048)	3 (2.0%)
Missense	g.25482C>T	c.676C>T	p.R226W	6	Reported (rs137852240)	6 (4.0%)
Missense	g.36020 G>A	c.1070G>A	p.G357E	8	Reported (rs137852275)	8 (5.33%)
Stop-gain	g.36044C>A	c.1094C>A	p.S365 ^{a)}	8	Not reported	15 (10.0%)
Missense	g.36137G>A	c.1187G>A	p.C396Y	8	Reported (rs137852273)	1 (0.66%)
Missense	g.36182 G>A	c.1232G>A	p.S411N	8	Reported (rs137852276)	3 (2.0%)
Synonymous	g.36335 A>G	c.1385A>G	p.Ter462=	8	Reported (rs561793582)	1 (0.66%)
3' UTR	g.37446A>G	c.*1110A>G	8	Not reported	3 (2.0%)

^{a)}NG_007994.1, NM_000133.4, and NP_000124.1 reference sequences were used for genomic DNA variant nomenclature, coding region variant nomenclature, and protein variant nomenclature, respectively. All nomenclatures were made according to Human Genome Variation Society (HGVS) guidelines.

patients with moderate HB. The novel stop-gain mutation c.1094C>A was found in 3 patients with moderate HB, with a mean FIX concentration of 2.6±0.8 and a mean age of onset of 6.5±0.5, as well as in 12 patients with severe HB, with a mean FIX concentration of 0.05±0.15 and a mean age of onset of 2±1.0. This mutation was observed at a high

rate among patients with severe HB. The following, previously described pathogenic mutations have been observed: c.127C>T in 3 mild (FIX concentration, 8.1±1.9), 4 moderate (FIX concentration, 2.1±0.2), and 2 severe (FIX concentration, 0.65±0.15) cases; c.470G>A in 3 mild (FIX concentration, 7.6±2.7), 5 moderate (FIX concentration, 2.9±0.9),

Table 3. Genotypic and phenotypic associations of the mutations recorded in the study population.

Mutation type	cDNA position	Patients			Factor IX (IX) concentration level (%)	Age of onset	Inhibitor-positive (N)	Inhibitor-negative (N)	Clinical significance
		m	M	S					
Missense	c.127C>T	03	04	02	6.5, 8.0, 10 (m) 2.0, 2.3, 1.8, 2.0 (M) 0.8, 0.5 (S)	10, 12, 8 (m) 7, 6, 9, 9 (M) 1, 1.5 (S)	2 (m) 2 (M) -	1 (m) 2 (M) 2 (S)	Pathogenic
Missense	c.195G>A	00	01	00	3.0 (M)	7.5 (M)	1 (M)	-	Likely pathogenic
Missense	c.197A>T	02	00	01	6.0, 9.0 (m) 0.3 (S)	13, 11 (m) 1 (S)	-	2 (m) 1 (S)	Likely benign
Missense	c.198A>T	00	04	07	1.5, 2.0, 2.5, 2.0 (M) 0.8, 0.5, 0.1, 0.6, 0.6, <0.01, 0.01 (S)	6, 7, 7, 8 (M) 1, 2, 1, 1.5, 2, 2, 1.6 (S)	4 (M) 4 (S)	- 3 (S)	Pathogenic
Stop-gain	c.223C>T	00	00	02	<0.01, <0.01 (S)	1, 1 (S)	1 (S)	1 (S)	Pathogenic
Missense	c.304C>T	02	00	00	12.0, 10.0 (m)	13, 10 (m)	2 (m)	-	Likely pathogenic
Missense	c.314A>G	00	01	03	2.0 (M) 0.2, 0.1, 0.01 (S)	8 (M) 1, 2, 1 (S)	-	1 (M) 3 (S)	Pathogenic
Missense	c.470G>A	03	05	09	5.0, 7.5, 10.3 (m) 2.0, 3.5, 2.5, 1.8, 4.0 (M) 0.8, 0.5, 0.01, 0.2, <0.01, <0.01, 0.4, 0.2, <0.01 (S)	6.5, 10, 11 (m) 5, 7, 7, 9, 7 (M) 1, 2, 2, 3, 2, 2, 1, 2 (S)	3 (m) 1 (M) 2 (S)	- 4 (M) 7 (S)	Pathogenic
Missense	c.580A>G	03	00	00	10.7, 9.0, 9.0 (m)	10, 8, 8 (m)	-	3 (m)	Likely benign
Missense	c.676C>T	00	01	05	4.0 (M) 0.5, 0.1, <0.01, 0.01, <0.01 (S)	5.5 (M) 3, 1, 2, 2, 1 (S)	1 (M) 1 (S)	- 3 (S)	Pathogenic
Missense	c.1070G>A	01	03	04	6.5 (m) 2.0, 3.8, 2.5 (M) 0.01, 0.1, <0.01, <0.01 (S)	12 (m) 6, 7, 7 (M) 2, 2, 2, 1 (S)	- 2 (M) 2 (S)	1 (m) 1 (M) 1 (S)	Pathogenic
Stop-gain	c.1094C>A	00	03	12	2.6, 3.5, 1.8 (M) 0.01, 0.01, 0.1, 0.2, <0.01, <0.01, 0.1, 0.01, <0.01, 0.01, <0.01, <0.01 (S)	7, 7, 6 (M) 1, 2, 2, 2, 2, 3, 1.5, 3, 2, 2, 2.5, 1 (S)	- 10 (S)	3 (M) 2 (S)	Pathogenic
Missense	c.1187G>A	00	00	01	0.6 (S)	2 (S)	-	1 (S)	Benign
Missense	c.1232G>A	00	00	03	0.6, 0.3, 0.1 (S)	2, 1, 1.5 (S)	1 (S)	2 (S)	Pathogenic
Synonymous	c.1385A>G	00	01	00	4.0 (M)	10 (M)	1 (M)	-	Benign
3' UTR	c.*1110A>G	01	03	00	12.0 (m) 5.0, 4.0, 3.8 (M)	13 (m) 7, 7.5, 9 (M)	1 (m) 1 (M)	- 2 (M)	-

Abbreviations: m, mild; M, moderate; S, severe.

Table 4. Pathogenicity predictions of the p.E66D mutation.

Mutation	PROVEAN ^{a)}	SNAP2 ^{b)}	PolyPhen2 ^{c)}	PHD-SNP ^{d)}	SNP&GO ^{e)}	PANTHER
E66D	Deleterious Score: -2.540	Effect Score: 37	Probably damaging Score: 0.999	Disease Score: 4	Disease Probability: 0.705	Probably damaging

^{a)}PROVEAN: "Deleterious" if the prediction score was ≤2.5, "Neutral" if the prediction score was ≥2.5. ^{b)}NAP2: "Neutral" if the score ranged from 0 to -100. "Effect" if the score was between 0 and 100. ^{c)}PolyPhen2: "Probably damaging" is the most disease-causing ability, with a score near 1. "Possibly damaging" signifies less disease-causing ability with a score of 0.5–0.8. "Benign", which does not alter protein function, with a score closer to 0. ^{d)}PHD-SNP: if the probability is >0.5, mutation is predicted as "Disease" and if less than <0.5, mutation is predicted to be "Neutral". ^{e)}SNP & GO: Probability of >0.5 is predicted to be a disease-causing nsSNP.

and 9 severe (FIX concentration, 0.1 ± 0.7) cases; c.676C>T in 1 moderate and 5 severe (FIX concentration, 0.1 ± 0.7) cases; c.1070G>A in 1 mild, 3 moderate (FIX concentration, 2.8 ± 0.8), and 4 severe (FIX concentration, 0.05 ± 0.1) cases; c.223C>T in 2 severe cases; and c.314A>G in 1 moderate and 3 severe (FIX concentration, 0.1 ± 0.09) cases. The remaining mutations were recorded at a low frequency. Detailed genotype-phenotype associations are explained in Table 3.

The novel missense mutation p.E66D was shown to be harmful to FIX protein function by PROVEAN, SNAP2, PholyPhen2, SNP&GO, PHD-SNP, and PANTHER (Table 4). Multiple sequence alignment of this novel missense mutation indicated that it was present in the highly conserved residue of the FIX protein (Fig. 2). Homology modeling of the protein structure was conducted using the Swiss model server, which was then visualized and analyzed using chimera program. In p.E66D, the mutant residue is smaller than wild type residue, which might lead to the loss of interactions with the metal ion: “calcium 4 or magnesium 1; via 4-carboxyglutamate” (Fig. 3). The novel stop-gain mutation, p.S365*, results in a premature stop codon that leads to a truncated FIX variant of 365 amino acids, corresponding to a loss of approximately 21% of the wild type FIX protein (Fig. 3).

DISCUSSION

HB is a bleeding disorder that causes abnormal or poor blood clotting. Pathogenic variants of the *F9* gene are known to cause this disorder [13]. FIX is an essential element in

the intermediate stage of the blood coagulation cascade. Nearly one third of hemophilia cases occur without any previous family history, but mainly due to new genetic variations [7]. In 1.3% to 7.8% of hemophilia cases, more than one mutation in the *F9* gene have been reported [14], and, in accordance with other reports, most of the mutations were single nucleotide variants [15]. Missense mutations were the most common single nucleotide variants in HB, accounting for more than 58.4%, whereas 15.4% were frameshift mutations resulting from deletions, insertions, or duplications. Nonsense and splice mutations accounted for 8.3% and 9.4% of the cases, respectively [6].

In the present study, we recorded a total of 16 mutations, of which 15 (93.75%) were coding sequence variants. The majority of them (81.25%) were missense variants.

We recorded the stop-gain mutation p.R75W in 2 patients with severe HB, which have been described previously by Parrado Jara *et al.* (2020) [5], Radic *et al.* (2013) [16], Kwon *et al.* (2008) [17], Saini *et al.* (2015) [18], and Koeberl *et al.* (1990) [19]. This mutation is known to result in the loss of >80% of total FIX protein and to increase the probability of an immune response. The p.R226W mutation affects zymogen activation processes by altering the cleavage of Factor XIa [20, 21], which was recorded in 1 moderate and 5 severe (FIX concentration, 0.1 ± 0.7) cases within our study group. The p.C396Y mutation was shown to disturb the environment of the active site that is involved in the conversion of the zymogen into an active enzyme, which was observed only in one severe case of HB [22]. We also recorded the p.T194A mutation in 3 mild HB cases (FIX concentration, 9.8 ± 0.8) and the p.C357Y missense mutation, which were




Fig. 2. Multiple sequence analysis of the Factor IX (FIX) protein. The arrow indicates the position of the p.E66D mutation.




Fig. 3. Segments of a 3D model of wild type (upper left panel) and mutant (p.E66D; upper right panel) Factor IX. A superimposed 3D model of wild type (red) and mutant (p.S365*; blue) Factor IX are shown in the lower panel.

predicted to be detrimental to FIX protein function in the blood coagulation process in previous studies. We recorded the latter mutation in 1 mild, 3 moderate (FIX concentration, 2.8 ± 0.8), and 4 severe (FIX concentration, 0.05 ± 0.1) cases [23–26]. R43 is a mutation hotspot that accounted for 73.5% of HB cases in the present study [27], and we recorded the R43W mutation in c.127C>T in 3 mild (FIX concentration, 8.1 ± 1.9), 4 moderate (FIX concentration, 2.1 ± 0.2), and 2 severe (FIX concentration, 0.65 ± 0.15) cases.

The novel missense mutation p.E66D was recorded in 4 patients with moderate HB, with a mean FIX concentration of 2.0 ± 0.5 , and in 7 patients with severe HB, with a mean FIX concentration of 0.3 ± 0.5 . It was found to be harmful to the function of the FIX protein by *in silico* pathogenicity prediction tools. Moreover, this novel mutation was found to be present in highly conserved regions of the FIX protein. The mutant p.E66D residue was found to be smaller than the wild type residue. This might have led to the loss of interactions with the metal ion: “calcium 4 or magnesium 1; via 4-carboxyglutamate”. Hence, this missense variant has detrimental effects on normal FIX activation and blood coagulation processes. According to the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines, p.E66D is classified as “pathogenic” [28]. Along with missense variants, we also recorded one novel stop-gain mutation, p.S365*, in 3 moderate HB cases, with a mean FIX concentration of 2.6 ± 0.8 , as well as in 12 severe HB cases, with a mean FIX concentration of 0.05 ± 0.15 . This led to the loss of 21% of FIX protein, which resulted in the loss of most of the peptidase S1 activity of the FIX protein. According to the ACMG/AMP guidelines, p.S365* is classified as “pathogenic.” Only one 3' UTR variant was recorded in our study cohort. Functional analysis of the mutations was the major limitation of our study.

Of the 150 HB patients, 90 (60%) had mutations in the F9 gene, including mild, moderate, and severe conditions. In the mild, moderate, and severe groups, 15 (10%), 26 (17%), and 49 (32%) of the patients showed mutations in the F9 gene. Among the 3 groups, the severe group showed a high rate of mutations (32%) compared to the other 2 groups; in our study cohort, the number of patients with severe HB was high, followed by moderate and mild groups (Table 1). Of the 16 mutations detected, 9 were identified as pathogenic. All of the 49 hemophilic patients with high mutation rates featured these 9 pathogenic variants: c.127C>T, c.198A>T, c.223C>T, c.314A>G, c.470G>A, c.676C>T, c.1070G>A, c.1094C>A, and c.1232G>A. These corresponded to the mutation locations causing the pathogenic effects that may have led to severe symptoms observed in hemophilic patients of our study population. Both c.1187G>A and c.1385A>G mutations were recorded as benign, and one moderately affected patient was diagnosed with the c.1385A>G variant, whereas the c.1187G>A mutation was found in a patient with severe HB. Two mutations, i.e., c.195G>A and c.304C>T, were likely pathogenic, and the c.195G>A variant was found in one patient with moderate

hemophilia. In two patients with mild disease, the c.304C>T mutation was found. The likely benign mutations c.197A>T and c.580A>G were recorded in 2 mild, 1 severe, and 3 mild cases of hemophilia, respectively.

Additionally, 2 stop-gain mutations and 7 missense mutations were major pathogenic variations or disease-causing mutations recorded in our study; patients who were carriers of these mutations showed more severe conditions compared to the other 2 groups (mild and moderate). Likely pathogenic and benign mutations were also missense mutations, and all the patients carrying these mutations were mildly to moderately affected by HB, except for 2 patients. Only 3 mutations (c.127C>T, c.470G>A, and c.1070G>A) were associated with different severities. Moreover, 2 mutations were only associated with mild HB (c.304C>T and c.580A>G), 2 mutations were associated with moderate HB (c.195G>A and c.1385A>G), and 3 mutations were only associated with severe HB (c.223C>T, c.1187G>A, and c.1232G>A). One mutation each was associated with mild-moderate (c.*1110A>G) and mild-severe HB (c.197A>T). In addition, 4 mutations were associated with moderate-severe HB (c.314A>G, c.198A>T, c.676C>T, and c.1094C>A). Among the patients with severe HB, 48% (49/102) featured mutations in the F9 gene, followed by 86.6% (26/30) and 83.3% (15/18) of moderate and mild HB cases, respectively.

In our study, we also observed clinical differences between the mutated and wild type F9 groups. The main clinical symptoms were lower FIX concentration levels ($5.5\pm 2.5\%$) in the mutated groups compared to the control group ($8.0\pm 2.5\%$). The inhibitor-positive rate was also high in patients carrying F9 mutations compared to patients with wild type F9 (40/38), but inhibitor-negative numbers were decreased in the mutated hemophilic patients (46/112). Different studies conducted on HB patients recorded remarkable allelic heterogeneity, consisting of similar mutations, which were associated with different phenotypes. Similar to the results obtained by previous studies, we also found that the same mutations resulted in multiple phenotypes/severities [29]. Studies conducted between 1993 and 2014 with 20 or more unrelated patients with HB showed that the F9 detection rate varied from 83% to 100% using PCR and Sanger sequencing [4], whereas in our study population, the mutation rate was 60%. Phenotypic heterogeneity and mutation rates among HB patients are largely unknown. External influences, such as the modification of genes, environmental factors, or epigenetic effects, are major factors in both cases.

Our study strongly suggests that the majority of HB cases feature pathogenic single nucleotide variations, which may be novel or previously recorded. In many cases, novel single nucleotide variants are involved. Population-based screening of mutations will help establish inhibitor risk prediction and carrier detection strategies in India.

ACKNOWLEDGMENTS

We thank all hemophilia societies and hemophilia B patients and their families for participating in this study. We thank the Karnataka Institute for DNA Research, Dharwad, India, for providing instrumentation support for the research work. We also thank Shri B. M. Patil Medical College, Hospital and Research Centre, BLDE (Deemed to be University), Vijayapura and S. Nijaliangappa Medical College, HSK Hospital and Research Center, Bagalkot, for their continuous support throughout this research project.

Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Yu T, Dai J, Liu H, et al. Spectrum of F9 mutations in Chinese haemophilia B patients: identification of 20 novel mutations. *Pathology* 2012;44:342-7.
2. Rosendaal FR, Smit C, Briët E. Hemophilia treatment in historical perspective: a review of medical and social developments. *Ann Hematol* 1991;62:5-15.
3. Mannucci PM. Treatment of hemophilia: recombinant factors only? No. *J Thromb Haemost* 2003;1:216-7.
4. Goodeve AC. Hemophilia B: molecular pathogenesis and mutation analysis. *J Thromb Haemost* 2015;13:1184-95.
5. Parrado Jara YA, Yunis Hazbun LK, Linares A, Yunis Londoño JJ. Molecular characterization of hemophilia B patients in Colombia. *Mol Genet Genomic Med* 2020;8:e1210.
6. Yuen LK, Zakaria Z, Yusoff YM, Esa E, Afandi FM, Karim FDA. A novel missense mutation of F9 gene in hemophilia B Patients. *J Blood Disord Transfus* 2017;8:383.
7. Bhattacharya DK. Haemophilia in the Indian Scenario. *Int J Hum Genet* 2006;6:33-9.
8. Kumar S, Sinha S, Bharti A, Meena LP, Gupta V, Shukla J. A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in North Eastern part of India. *J Family Med Prim Care* 2019;8:2463-7.
9. Yi S, Yang Q, Zuo Y, et al. A novel missense mutation in F9 gene causes hemophilia B in a family with clinical variability. *Blood Coagul Fibrinolysis* 2020;31:121-6.
10. Geddes VA, MacGillivray RT. The molecular genetics of hemophilia B. *Transfus Med Rev* 1987;1:161-70.
11. Li T, Miller CH, Payne AB, Craig Hooper W. The CDC hemophilia B mutation project mutation list: a new online resource. *Mol Genet Genomic Med* 2013;1:238-45.
12. Simhadri VL, Hamasaki-Katagiri N, Lin BC, et al. Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B. *J Med Genet* 2017;54:338-45.
13. Zahari M, Sulaiman SA, Othman Z, Ayob Y, Karim FA, Jamal R. Mutational profiles of F8 and F9 in a cohort of haemophilia A and haemophilia B patients in the multi-ethnic Malaysian population. *Mediterr J Hematol Infect Dis* 2018;10:e2018056.
14. Huang L, Li L, Lin S, et al. Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations. *Mol Genet Genomic Med* 2020;8:e1482.
15. Abla Z, Mouloud Y, Hejer EM, et al. Mutations causing hemophilia B in Algeria: identification of two novel mutations of the factor 9 gene. *Biodiversitas* 2018;19:52-8.
16. Radic CP, Rossetti LC, Abelleiro MM, et al. Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B. *Thromb Haemost* 2013;109:24-33.
17. Kwon MJ, Yoo KY, Kim HJ, Kim SH. Identification of mutations in the F9 gene including exon deletion by multiplex ligation-dependent probe amplification in 33 unrelated Korean patients with haemophilia B. *Haemophilia* 2008;14:1069-75.
18. Saini S, Hamasaki-Katagiri N, Pandey GS, et al. Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B. *Haemophilia* 2015;21:210-8.
19. Koeberl DD, Bottema CD, Sarkar G, Ketterling RP, Chen SH, Sommer SS. Recurrent nonsense mutations at arginine residues cause severe hemophilia B in unrelated hemophiliacs. *Hum Genet* 1990;84:387-90.
20. Suehiro K, Kawabata S, Miyata T, et al. Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by tryptophan and its activation by alpha-chymotrypsin and rat mast cell chymase. *J Biol Chem* 1989;264:21257-65.
21. Bertina RM, van der Linden IK, Mannucci PM, et al. Mutations in hemophilia B occur at the Arg180-Val activation site or in the catalytic domain of factor IX. *J Biol Chem* 1990;265:10876-83.
22. Taylor SA, Deugau KV, Lillicrap DP. Somatic mosaicism and female-to-female transmission in a kindred with hemophilia B (factor IX deficiency). *Proc Natl Acad Sci U S A* 1991;88:39-42.
23. Li Y, Bezemer ID, Rowland CM, et al. Genetic variants associated with deep vein thrombosis: the F11 locus. *J Thromb Haemost* 2009;7:1802-8.
24. Graham JB, Lubahn DB, Lord ST, et al. The Malmö polymorphism of coagulation factor IX, an immunologic polymorphism due to dimorphism of residue 148 that is in linkage disequilibrium with two other F.IX polymorphisms. *Am J Hum Genet* 1988;42:573-80.
25. McGraw RA, Davis LM, Noyes CM, et al. Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX. *Proc Natl Acad Sci U S A* 1985;82:2847-51.
26. Miyata T, Sakai T, Sugimoto M, et al. Factor IX Amagasaki: a new mutation in the catalytic domain resulting in the loss of both coagulant and esterase activities. *Biochemistry* 1991;30:11286-91.
27. Gao W, Xu Y, Liu H, et al. Characterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay. *Blood Adv* 2020;4:3659-67.
28. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405-24.
29. Chavali S, Sharma A, Tabassum R, Bharadwaj D. Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX. *Proteins* 2008;73:63-71.